NEW in @Health_Affairs: NPC & @TuftsCEVR captures how commercial plans often take 6+ months to update coverage after FDA label revisions and move faster to restrict access than expand it.
Timeliness matters for patient access. Read the study: https://t.co/600MJTx66C
Some policy proposals view lowering prices and expanding access to treatments as a zero-sum game. But America can do both at the same time and build on decades of cancer-fighting progress. Read the full perspective here: https://t.co/TL0pHEZkLy (4/4)
America is winning the war on cancer, but recent policies such as the Inflation Reduction Act are putting 55 years of progress at risk. As @drjmob writes in @TheCancerLetter, we can protect affordability without stalling innovation ๐งต(1/4)
CMS and policymakers can still change course. By recognizing the value of innovative treatments, supporting combination therapies, and negotiating treatments with care, we can ensure those counting on innovative treatments receive them. (3/4)
John O'Brien (@npcnow): "The treatments we now have would have been science fiction when I was in pharmacy school. The sustained, high-risk investments from scientists at drug companies have yielded remarkable innovations."
https://t.co/CUqC92II56
Inย a newย @AJMC_Journalย article, my @npcnow colleagues and I explore what American patients value and whether foreign health technology assessment (HTA) bodies incorporate American patientsโ values.
Read more here: https://t.co/aVuxUKd1Gi
A new article in @AJMC_Journal explores what American patients value and whether foreign health technology assessment (#HTA) bodies incorporate American patientsโ values. It looks at two key dimensions: patient access and autonomy, and the breadth of treatment impacts considered.
New research from the National Pharmaceutical Council (#NPC)ย supports consistent andย equitableย patient access to #genetherapies. Read more in @SpringerNatureโs PharmacoEconomics at https://t.co/adjNLDxkJe
A new @amcporg JMCP commentary from NPC's Kimberly Westrich describes new regulatory requirements for patient engagement and outlines opportunities for the managed care community to expand the role of patients in healthcare decision-making.ย
๐Read it at https://t.co/XNqET8U9OB
Our SVP Stephanie Krenrich joined a great panel at AMCP Nexus today on 340B, with @ashpofficial's Jillanne Schulte Wall, @npcnow's Kimberly Westrich, and @umdlaw's Bill Sarraille.
Thanks @amcporg for highlighting this critical healthcare policy for community health centers!
๐ฅ ๐๐๐๐ 2026 ๐๐ฉ๐จ๐ญ๐ฅ๐ข๐ ๐ก๐ญ: ๐๐ซ๐จ๐ฌ๐ฌ๐๐ข๐ซ๐ โ ๐๐ก๐ 340๐ ๐๐ซ๐ฎ๐ ๐๐ซ๐ข๐๐ข๐ง๐ ๐๐ซ๐จ๐ ๐ซ๐๐ฆ ๐ฅ
The #340B program is one of the most consequential issues in healthcare today. At the ๐๐ซ๐ฎ๐ ๐๐ก๐๐ง๐ง๐๐ฅ๐ฌ ๐๐๐๐๐๐ซ๐ฌ๐ก๐ข๐ฉ ๐ ๐จ๐ซ๐ฎ๐ฆ 2026, two of the industryโs most influential voices will go head-to-head:
โ Maureen Testoni, JD, President & CEO, @340BHealth
โ John O'Brien, PharmD, MPH, President & CEO, National Pharmaceutical Council @npcnow
Moderated by:
๐๏ธLuke Greenwalt, MBA, Vice President and Lead, @IQVIA_US Market Access Center of Excellence
This session promises a candid, high-stakes exchange you wonโt want to miss!
๐๏ธ Request an Invite: https://t.co/YaqMryoiWO
#DCLF2026 #DrugPricing #HealthPolicy
Kimberly Westrich, MA, chief strategy officer at @npcnow, told #AJMC at #AMCP2025 about the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and #Medicaid committees.
Watch here: https://t.co/R8ouf6Iw4d
๐กAll but one reported they were more likely to consider a larger launch indication for products they invest in & may wait longer to enter clinical development to have a better chance of success with a larger indication rather than starting sooner with a smaller indication. (5/5)
Investors across a range of stages, investment sizes, and fund types frequently reported that the #IRA of 2022 is exacerbating challenges in bringing innovative new medicines to market, according to new research in @Health_Affairs at https://t.co/6WeA4ydC2R ๐งต
๐กMore than three quarters (77%) of investors shared that the IRAโs โ#pillpenaltyโ has created a disincentive to investing in small molecules
(4/5)